For example, we showed previously that relative expression of proliferation-related and immune response-related genes, i.e., UBE2C, TOP2A, RRM2, FOXM1, MK167, and BTN3A2, provided a prediction value of adjuvant chemotherapy benefit for patients with ER+/HER2− early breast cancer [18]. The gene discussed is RRM2; the disease is breast cancer.